News Search Results
Jul 08, 2025, 09:00 ET Sensorium Therapeutics Receives FDA IND Clearance for SNTX-2643, a First-in-Class, Rapid-Acting Anxiolytic
Harvard Medical School professor—as Chief Executive Officer. Dr. Hooker is a world-renowned expert in chemical neuroscience, biomarker development, and CNS pharmacology. He has co-founded and advised several biotech companies, including Eikonizo Therapeutics, Delix Therapeutics, and Rocket Science Health.
More news about: Sensorium Therapeutics, Inc
Jul 08, 2025, 03:30 ET Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson's Disease
Neuraxpharm's commitment to realising innovative solutions in CNS care. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders.
More news about: Neuraxpharm
Jul 07, 2025, 14:22 ET Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid
nervous system (CNS) cancers, announced the results of the analytical validation study of the Belay Vantage™ assay for detection of MGMT (Methylation of the O6-methylguanine-DNA methyl-transferase) promoter methylation in cerebrospinal fluid (CSF) for primary and metastatic CNS cancers as
More news about: Belay Diagnostics
Jul 07, 2025, 07:00 ET Cooper University Health Care Selects Corero Network Security to Implement Zero Trust Admission Control
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced that
More news about: Corero Network Security
Jul 03, 2025, 06:07 ET MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
targeting)~30% CAR+ CD8+ T-cell generation from a single low dose in NHPB-cell depletion via in vivo CAR-T in NHPsBBB-crossing delivery in CNS murine modelsWhat's next? MOTE is raising >$40M in Series A funding to support IND-enabling
More news about: MOTE
Jul 02, 2025, 10:00 ET iQure Pharma Appoints Former UCB Chief Medical Officer and Head of Development, Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor
2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced the appointment of Prof. Dr. Iris Loew-Friedrich as Clinical and R&D Advisor.
More news about: iQure Pharma Inc.
Jul 02, 2025, 09:00 ET Headlands Research Enters the Caribbean with Acquisition of CMRCenter
sponsors a turnkey, single-contract gateway to one of the largest Hispanic patient populations under FDA oversight and accelerating enrollment for vaccine, CNS, and specialty studies.
More news about: Headlands Research
Jun 30, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed
More news about: NLS Pharmaceutics AG
Jun 27, 2025, 07:00 ET Corero Network Security Joins World Wide Technology as Certified Partner to Advance Cyber Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced it has been named a Certified Partner in the
More news about: Corero Network Security
Jun 26, 2025, 11:44 ET Eternum LLC Acquires Renewal Kit for Travelers™, Launches Goal Time™ -- A Science-Backed Travel Resilience Supplement for All Travelers
travel." Formulated with the guidance of renowned clinical nutritionist Dr. Patti Milligan, PhD, RD, CNS, Goal Time™ is engineered to support the systems most affected by travel: energy, digestion, and immunity. Dr. Milligan invites
More news about: Eternum LLC
Jun 26, 2025, 08:30 ET STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer
discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases. STORM's lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15
More news about: STORM Therapeutics
Jun 26, 2025, 08:03 ET HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation ("TMS") as well as medication management. Dr. Cohen is an Interventional
More news about: NRx Pharmaceuticals, Inc.
Jun 25, 2025, 12:29 ET Access Free Educational Videos and Webinars Provided by the Multiple Sclerosis Association of America
Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
Jun 24, 2025, 17:19 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:18 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:10 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:04 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:00 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 09:00 ET Cohen & Steers Appoints Brad Ispass as Head of Enterprise Wealth
YORK, June 24, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Brad Ispass as Head of Enterprise Wealth, a newly created role that will lead the
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 06:30 ET Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
has limited brain penetrance, ± chemotherapy (n = 13), the IC-ORR was 85% with 54% (7/13) intracranial CRs. There was only one CNS progression event among CNS responders.Intracranial responses were also observed in patients previously treated with the brain-penetrant TKIs entrectinib,
More news about: Nuvalent, Inc.
Jun 23, 2025, 17:34 ET Cohen & Steers Closed-End Funds Declare Distributions for July, August and September 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 23, 2025, 16:30 ET Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Jun 22, 2025, 22:01 ET IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
is characterized by focal lymphocytic CNS infiltration leading to myelin destruction and axonal damage, which result in neurologic syndromes and physical disability[3]. MS clinical manifestations depend on the location of lesions in the CNS. Symptoms may include sensory and visual
More news about: IASO Bio
Jun 20, 2025, 09:00 ET Mitsubishi Tanabe Pharma America Highlights Parkinson's Disease Research at 2025 EAN and ATMRD Congresses
combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at
More news about: Mitsubishi Tanabe Pharma America
Jun 19, 2025, 09:00 ET Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent
More news about: Indivior PLC